FDA News Analysis

Lilly buys 4E in non-opioid pain push: what investors should watch

FDA · moderate to severe acute pain · 6 min

FDA MRD guidance in multiple myeloma: what BD teams should track

FDA · multiple myeloma · 6 min

Vabysmo gains EU approval for retinal vein occlusion: what changes next

FDA · retinal vein occlusion · 6 min

FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain

FDA · moderate-to-severe acute pain · 7 min

Lenacapavir posts 100% HIV prevention in PURPOSE 1

FDA · HIV · 8 min

Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial

FDA · Alzheimer's disease · 6 min

FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx

FDA · moderate-to-severe acute pain · 8 min

Vertex launches Journavx after FDA approval for acute pain

FDA · oncology · 9 min

Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis

FDA · rare disease · 5 min

Amneal Romidepsin FDA Approval: B2B Analysis for BD Teams and Investors

FDA · 6 min

FDA Flavored Vape Ban: Youth Risk and Pharma Implications

FDA · 4 min

Listeria Outbreaks 2026: FDA and CDC Soft Cheese Recall Analysis for Pharma

FDA · oncology · 6 min